Holders — by stockHoldings — by fund
Nan Fung Group Holdings Ltd
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001782539
$131.5M
disclosed book value
25
positions
26.5%
largest position share
Positions, as of 2026-06-30
top 25 of 25 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | MPLTMAPLIGHT THERAPEUTICS INC | 971,253 | $34.8M | 26.5% |
| 2 | LBRXLB PHARMACEUTICALS INC | 630,657 | $20.5M | 15.6% |
| 3 | EVMNEVOMMUNE INC | 1.4M | $19.2M | 14.6% |
| 4 | HELPCYBIN INC | 987,222 | $6.5M | 5% |
| 5 | INCYINCYTE CORP | 53,742 | $6.1M | 4.6% |
| 6 | RYTMRHYTHM PHARMACEUTICALS INC | 49,120 | $5.5M | 4.1% |
| 7 | ONCBEONE MEDICINES LTD | 15,722 | $4.5M | 3.4% |
| 8 | OCULIS HOLDING AG | 300,565 | $4.2M | 3.2% |
| 9 | ASCENDIS PHARMA A/S | 13,600 | $3.6M | 2.8% |
| 10 | RVMDREVOLUTION MEDICINES INC | 19,253 | $3.6M | 2.7% |
| 11 | KYMRKYMERA THERAPEUTICS INC | 30,875 | $3.5M | 2.7% |
| 12 | MDGLMADRIGAL PHARMACEUTICALS INC | 5,672 | $3.0M | 2.3% |
| 13 | CELCCELCUITY INC | 28,300 | $3.0M | 2.3% |
| 14 | ACADACADIA PHARMACEUTICALS INC | 102,984 | $2.6M | 2% |
| 15 | ARGXARGENX SE | 2,800 | $2.6M | 2% |
| 16 | RXRXRECURSION PHARMACEUTICALS IN | 595,287 | $2.2M | 1.7% |
| 17 | PCORPROCORE TECHNOLOGIES INC | 53,299 | $2.2M | 1.6% |
| 18 | HRMYHARMONY BIOSCIENCES HLDGS IN | 27,049 | $984,854 | 0.7% |
| 19 | INSMINSMED INC | 6,580 | $701,560 | 0.5% |
| 20 | ETHAISHARES ETHEREUM TR | 50,549 | $601,028 | 0.5% |
| 21 | IBITISHARES BITCOIN TRUST ETF | 15,968 | $531,575 | 0.4% |
| 22 | CHYMCHIME FINL INC | 21,075 | $431,616 | 0.3% |
| 23 | RANIRANI THERAPEUTICS HLDGS INC | 493,584 | $375,321 | 0.3% |
| 24 | TRDAENTRADA THERAPEUTICS INC | 49,082 | $361,244 | 0.3% |
| 25 | BOLTBOLT BIOTHERAPEUTICS INC | 5,000 | $19,250 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.